Week of June 12th-16th, 2017
Check back often for weekly updates
Stand Up To Cancer – Dream Team Translational Research Grant ($10,000,000 award, deadline September 5th, 2017). The Stand Up To Cancer Dream Team Translational Research Grant will fund a translational cancer research project that will address critical problems in patient care, including prevention strategies for those at risk, and deliver near-term patient benefit through investigation by a multidisciplinary, multi-institutional, collaborative Dream Team of expert investigators.
The ideas may focus on particular organ sites, patient populations (such as pediatrics) or on innovative methods of treatment. Projects must be designed to accelerate the application of new preventive, diagnostic or therapeutic approaches to the clinic (i.e., lead to patient involvement within 2-3 years from the beginning of the grant). Proposals for Dream Team research projects must present plans indicating how the work will be translated into the clinic. The ideas should be based on perceived opportunities for success as well as high-priority areas with a critical need for rapid progress beyond current medical care. Proposals for Dream Team research projects must present plans indicating how the work will be translated into the clinic. The ideas should be based on perceived opportunities for success as well as high-priority areas with a critical need for rapid progress beyond current medical care. Through a partnership with leading health care research and innovation collaborative OptumLabs, each team will have the ability to conduct research using OptumLabs’ proprietary database of de-identified claims and electronic health record data, analytic tools, and research support to pursue the proposed goals of the Dream Team. Collaboration with OptumLabs provides researchers access to real world data to support health service and population health research.
OptumLabs will be conducting information sessions for applicants who are interested in learning more about the OptumLabs Data Warehouse. If you would like more information or to register to attend, please email email@example.com by August 1, 2017 and include your name, institution and Dream Team Leader name. OptumLabs will contact interested parties about next steps, including dates and times of the information sessions. Grant Amount $10,000,000 USD. The AACR requires applicants to submit an electronic Letter of Intent via proposalCENTRAL by 12:00 pm (noon), Eastern Time on Tuesday, September 5, 2017 using the proposalCENTRAL website at http://www.proposalcentral.altum.com.
PCORI – Pragmatic Clinical Studies to Evaluate Patient-Centered Outcomes – Cycle 2 2017 (Up to $10 million award, Letter of Intent deadline July 25th, 2017). Notice of Upcoming PCORI Funding Announcement (PFA): PCORI seeks to fund pragmatic clinical trials, large simple trials, or large-scale observational studies that compare two or more alternatives for addressing prevention, diagnosis, treatment, or management of a disease or symptom; improving healthcare system-level approaches to managing care; communicating or disseminating research results to patients, caregivers, or clinicians; or eliminating health or healthcare disparities. Proposed studies must address critical clinical choices faced by patients, their caregivers, clinicians, or delivery systems. They must involve broadly representative patient populations and be large enough to provide precise estimates of hypothesized effectiveness differences and to support evaluation of potential differences in treatment effectiveness in patient subgroups. PCORI’s multi-stakeholder panels have identified 15 high-priority topics and research questions. PCORI will give first consideration to applications that directly address one or more of the 15 PCORI-identified topics. Note that PCORI is open to receiving and reviewing LOIs for studies on investigator-initiated CER questions as well. In addition, for this cycle, PCORI is indicating a Special Area of Emphasis for the following topic from the high-priority topic list: Anxiety Disorders in Children, Adolescents, and/or Young Adults. Compare the effectiveness of one or more digital applications of cognitive behavioral therapy (CBT) to an appropriate active control (e.g., face-to-face CBT) for treatment of mild-to-moderate anxiety in children, adolescents, and/or young adults (through age 25 years). Digital applications may include computer-based therapy (e.g., delivered via the Internet, downloadable software) and/or smartphone applications of CBT that are appropriate for treatment of anxiety. PCORI has a preference for digital interventions available in the public domain to support accessibility of effective treatments. PCORI is particularly interested in: Comparisons of treatment outcomes important to patients across CBT interventions with differing levels and types of support (e.g., parent, therapist, peer, and/or school counselor involvement); Studies in pediatric and primary care clinics, community mental health centers, schools, community social service organizations; Broad patient populations (e.g., comorbidities, range of severity) and a spectrum of developmental stages represented by patients ages 5 through 25 years old; Outcomes to include child and family functioning, symptom response, progression, acceptability of and adherence to recommended care; and, Two to three years of follow-up from baseline/randomization, with a minimum of 12 months. Applicants should make clear the length of the active intervention and whether maintenance or booster sessions are included. Any proposed interventions should be justified with efficacy data applicable to the population. Studies must capture primary and comorbid diagnoses (anxiety or otherwise), co-treatments, and measures of anxiety severity for potential heterogeneity of treatment response analyses. Please note that this funding program does not support applications to conduct cost-effectiveness analyses, systematic reviews (with or without meta-analyses), or developing or evaluating shared decision-making or decision-support tools. In general, PCORI will not cover costs for interventions that are being compared in the proposed study. This PFA preannouncement is provided to allow potential applicants additional time to identify collaborators, obtain stakeholder input on the research question, and develop responsive, high-quality proposals. Further details will be available in the full announcement to be released on June 23, 2017. Total Direct Costs: $10 million. Funds Available Up To $90 million.
American Heart Association – Vascular Disease Strategically Focused Research Network RFA ($3,709,200 award, deadline August 1st, 2017). Purpose: Vascular diseases, including atherosclerotic peripheral vascular and aortic diseases are prevalent in the U.S. and other nations. More than 202 million people worldwide suffer from peripheral artery disease, including more than 8 eight million in the U.S. It affects approximately 12-20% of individuals older than age 60. Additionally, individuals with PAD suffer about a 5 percent annual rate of major adverse cardiovascular events. If left untreated or inadequately treated, these disorders may become life-threatening and disabling.
The intent of this initiative is to support a collaboration of basic, clinical and population researchers from different disciplines whose collective efforts will lead to new approaches to study vascular disease, particularly Peripheral Artery Disease and Aortopathy. Population studies are inclusive of projects ranging from cohort studies to translational work involving community interventions. This Strategically Focused Research Network provides AHA with a mechanism to enhance the understanding of the causes, biology, pathophysiology and epidemiology of these disorders, and to develop more effective ways to prevent and treat them with ultimate improvement in outcomes. Vascular Diseases, specifically Peripheral Artery Disease (PAD) and/or Aortic Disease, constitute a broad array of disorders, but applications responsive to this SFRN RFA must focus specifically on peripheral artery disease and aortic diseases in order to enhance synergy among centers and within the network. Applications focusing on other vascular diseases, such as: coronary artery disease; cerebrovascular disease; acute and chronic venous diseases including venous thromboembolism, venous insufficiency and varicose veins; pulmonary and systemic hypertension; vasospasm; lymphedema; or vasculitis will NOT be considered. The intent of this initiative is to support a collaboration of basic, clinical and population researchers from different disciplines whose collective efforts will lead to new approaches to study vascular disease, particularly Peripheral Artery Disease and Aortopathy. Population studies are inclusive of projects ranging from cohort studies to translational work involving community interventions. Duration: 4 years with the opportunity for up to a 12-month No-Cost Extension. Award Amount: The maximum budget amount an applicant may request is $3,709,200. The AHA reserves the right to determine the final award amount for competitive projects based on need and potential impact.
National Multiple Sclerosis Society – multiple opportunities:
· Collaborative MS Research Centers ($750,000+ awards, pre-proposal deadline August 30th, 2017). As part of its overarching goals of stopping MS progression, restoring function, and ending MS forever, the National MS Society offers special funding for Collaborative MS Research Centers to help stimulate collaboration and interaction in MS research among independent investigators, strengthen the ties between basic and clinical research, and stimulate recruitment of researchers from other fields into MS research. This will serve to leverage already available research support. To be considered for funding, all projects must show relevance to the Society's research mission of stopping MS progression, restoring function and improving quality of life, and preventing MS. The maximum amount that can be requested from the Society made under this program is $150,000 per year in direct costs, for a term of five years, for a total of $750,000. Additional indirect costs will be applied according to applicable Society policies.
· Harry Weaver Neuroscience Scholar Awards ($375,000 award, deadline August 9th, 2017). As part of its overarching goals of stopping MS progression, restoring function, and ending MS forever, the National MS Society offers a limited number of Harry Weaver awards to highly qualified candidates who have concluded their research training and begun academic careers as independent investigators in an area related to multiple sclerosis. The awards are designed to provide salary and grant support for a five year period, thus permitting the awardee to establish competence in his/her chosen research area. Application must be made jointly by a candidate and the institution in which an appointment is held. The award includes both salary and research support, for a non-renewable five-year period paid through the sponsoring institution. a) Salary: The candidate must spend at least 20% of his or her time working on the research award to request salary support. Up to 75% of annual salary support may be requested (but in no case exceed $75,000 in the first year), with a 3% annual increase in each of the remaining 4 years. The total salary may be supplemented by funds from other sources (but not from private practice) to a level commensurate with the current pay scale of the sponsoring institution. Salary Cap: The Society will not pay pro-rated salaries that exceed $199,700. b) Research Support: The maximal direct costs that may be requested in the grant budget of the award is $30,000 in the first year, increasing incrementally each year up to $40,000 in the last year.
· Sylvia Lawry Physician Fellowships ($195,000 award, deadline August 9th, 2017.) With the increasing number of new therapies being developed for use in MS, there is a need for physicians trained in conducting clinical trials. To this end, the Society established the Sylvia Lawry Physician Fellowship Program, named in honor of its founder. Clinical trials to test the safety and efficacy of therapies for multiple sclerosis are highly complex and require special expertise and knowledge to monitor this highly variable disease. This program provides the individual with an MD or equivalent medical degree with up to 3 years of formal training, under the tutelage of an established investigator, in key elements associated with conducting clinical trials in MS. Residents who have or will have received training in neurology or physiatry in the United States, and who are in the PGY3 or PGY4 stage or beyond, are eligible to apply. Duration of Award: This award may be made for a period of up to three years. Salary and Tuition Costs: Up to $65,000 per year may be requested for salary, fringe benefits and/or tuition costs.
Cystic Fibrosis Foundation – two opportunities:
· LeRoy Matthews Physician-Scientist Award ($605,000 award, deadline September 13th, 2017). The award encourages outstanding newly trained pediatricians and internists to enhance clinical proficiency in CF-related sub specialties and to develop the necessary research capabilities to become independent biomedical investigators. The award provides individuals who are either enrolled in or are about to enroll in sub specialty training with the opportunity to undertake up to six (6) years of support for their clinical training, research training, and the initiation of their research career. It is anticipated that the award will provide the opportunity for clinicians to obtain sub specialty training, to develop into independent investigators, and to initiate a research program. The institutional environment must be one which stimulates and increases interaction between basic scientists and clinical investigators, and which indicates a strong commitment to CF research and care. Thus, applications from domestic medical schools made on behalf of candidates will be accepted if the institution meets the following criteria: Have a strong, established CF-related research and clinical training program; Have an adequate number of high-trained faculty in clinical and basic science related to CF; and, Show a commitment and capability to provide guidance to clinically-trained individuals in the development of independent careers as CF researchers and clinicians. Please refer to the attached Word document for further detail on application guidance.
· Postdoctoral Research Fellowship Award ($128,550 award, deadline September 6th, 2017). Two-year postdoctoral research fellowship awards are offered to M.D.s, Ph.D.s, and M.D./Ph.D.s who are interested in conducting basic or clinical research related to cystic fibrosis. A third year of support may be available as an option to highly qualified candidates, and will be considered after completion of 18 months of CFF-supported training. Application Deadline: Wednesday, September 6, 2017 at 5:00 PM (ET).
Warren Alpert Foundation and Harvard Medical School - Warren Alpert Prize ($500,000 award, deadline October 31st, 2017). The Warren Alpert Foundation Prize recognizes one or more scientists whose scientific achievements have led to the prevention, cure or treatment of human diseases or disorders, and/or whose research constitutes a seminal scientific finding that holds great promise of ultimately changing our understanding of and/or ability to treat disease. The value of the prize is U.S. $500,000 (to be split equally if more than one recipient is selected), a citation and plaque.
Gerber Foundation – Research Award ($350,000 award, two upcoming funding cycles with December 1st, 2017 and June 1st, 2018 deadlines for concept papers.) Pediatric Research Focus Areas: Pediatric Health; Pediatric Nutrition; and, Environmental Hazards. The Foundation’s mission focuses on infants and young children. Accordingly, priority is given to projects that improve the nutrition, care and development of infants and young children from the first year before birth to three years of age. The Foundation is particularly interested in fresh approaches to solving common, everyday problems or emerging issues within our defined focus area. Projects should focus on issues faced by care providers that, when implemented, will improve the health, nutrition and/or developmental outcomes for infants and young children. The board is particularly looking for practical solutions that can be easily and rapidly implemented on a broad scale with a predictable time frame to clinical application. Major target areas for research include: New diagnostic tools that may be more rapid, more specific, more sensitive, less invasive; New treatment regimens that are improved or novel, less stressful or painful, more targeted, have less side effects, provide optimal dosing; Symptom relief; Preventative measures; Assessment of deficiencies or excesses (vitamins, minerals, drugs, etc.); and, Risk assessment tools or measures for environmental hazards, trauma, etc. Note that the Foundation is looking for projects that will result in ‘new’ information, treatments or tools that will result in a change in practice. The board rarely funds projects that are focused on sharing current information with parents or caregivers (parent or provider educational programs). Novice Researchers: Applications for Novice grants follow the same process as regular grants and are limited to no more than $20,000 in total (inclusive of indirects). They are identified by the amount requested in the application. Organizations may submit as many concept papers at a time as they wish. Selection of concept papers are based upon the overall quality of the research and a determination of best fit with the Foundation’s goals. We do prefer that PI’s submit no more than one concept paper during any given cycle. Awards and time periods vary depending upon the specific project. Research projects may be no longer than 3 years in length. Total grant size should be no more than roughly $350,000.
Pfizer – Call for Grant Applications – Vaccine Preventable Diseases in the IBD Patient ($250,000 award, deadline July 28th, 2017). The intent of this CGA is to encourage organizations to design educational programs to reach gastroenterologists and gastroenterology fellows, nurse practitioners, physician assistants, and all other healthcare professionals involved in the care and treatment of adult patients with inflammatory bowel disease (IBD). Programs with the highest likelihood of improving clinical gastroenterologists’ and gastroenterology fellows’, nurse practitioners, physician assistants’, and all other healthcare professionals’ understanding of the current vaccination guidelines and the importance of vaccination in the care of IBD patients will be given the highest priority. Individual projects requesting up to $250,000 will be considered.
Elsa U. Pardee Foundation – Research Grant Program (typical grant range $120,000 - $180,000 with 15% IDC’s, two upcoming funding cycle deadlines – August 31st, 2017 and December 31st, 2017). The Elsa U. Pardee Foundation funds research to investigators in United States non-profit institutions proposing research directed toward identifying new treatments or cures for cancer. The Foundation particularly encourages grant applications for a one year period which will allow establishment of capabilities of new cancer researchers, or new cancer approaches by established cancer researchers. It is anticipated that this early stage funding by the Foundation may lead to subsequent and expanded support using government agency funding. Project relevance to cancer detection, treatment, or cure should be clearly identified.
Sarcoma Alliance for Research Through Collaboration ($100,000 award, deadline January 8th, 2017). The SARC Sarcoma SPORE Career Development program was initiated to support the ideas and work of investigators that complement the depth of sarcoma translational research and to help ensure the continual renewal of high-quality scientific endeavors in the SARC Sarcoma SPORE. Career Development Awards are awarded in the amount of $100,000 for one year only. The second year award is pending availability of funds and satisfactory progress of the project.